Artigo Revisado por pares

Abstracts: Turkish Society of Molecular Medicine, Third International Congress of Molecular Medicine, May 5-8, 2009, Istanbul, Turkey

2009; Wiley; Volume: 61; Issue: 3 Linguagem: Inglês

10.1002/iub.183

ISSN

1521-6551

Autores

Turgay İşbir,

Tópico(s)

Nutrition, Genetics, and Disease

Resumo

Dear Colleagues, On behalf of the Turkish Society of Molecular Medicine, it is my great pleasure to welcome you to our III. International Congress of Molecular Medicine. The comprehensive scope of our meeting, addressing the interests of physicians, scientists and other healthcare professionals and the industry, may be challenging to all at the same time. We aim to merge our interest in molecular medicine and to establish a link between basic and clinical sciences. For the clinician, there is the opportunity to focus on advances in the basic sciences forming the basis of clinical practice. For the scientist, there is a perspective to appreciate the wide-reaching clinical relevance of scientific discovery. A large part of the programme is devoted to invited speakers and poster presentations. The Molecular Medicine Congress participants will receive CME credits from the Turkish Medical Society. We are confident that your stay in Istanbul will be both academically and socially rewarding, and we look forward to meeting with you personally at the III International Congress of Molecular Medicine. Prof. Dr. Turgay Isbir Chairperson of Turkish Society of Molecular Medicine COMMITTEES Honorary President Yunus Soylet Congress President Turgay Isbir Vice Presidents Necip Ilhan, Nezih Hekim International Scientific Steering Committee Angelo Azzi Efstathios S. Gonos Shant Kumar Franz Theuring John G. Delinassios Robert Huber Aldo Tomasi Kurt Wüthrich Organization Committee Bedia Agachan Nilüfer Bozkurt Yigit Ilhan Eraltan Atike Tekeli Bülent Yigit Mehmet İsbir Didem Kafadar Tomris Ozben Tülin Ozturk Nevin Ilhan Selim Isbir Umit Zeybek Alper Tunga Akarsubasi H. Arzu Ergen Uzay Gormus Hulya Yilmaz Guzide Yucebilgic Ertugrul Kahraman Fehmi Narter Oguz Ozturk Lulufer Tamer Tamer Inal Makbule Aydin Sertac Kip Yesim Negis Scientific Committee Kemal Altas Hüseyin Bagci Ahmet Belce Turgay Budak Mahmut Carin Esen O. Dural Kemal Erbil Stefano Frosina Kishorchandra Gohil Emin Kansu Güldal Kirkali Zehra Bugra Nesrin Emekli Figen Gurdol Ilker Durak Gultekin Yucel Nedret Kilic Mehmet Kurtoglu Adile Muz Fatma Oguz Moshe Phillip Ahmed El Sohemy Yaman Tekant Seyhan Tukel Engin Ulukaya Gary Williamson Selma Yilmazer Kadirhan Sunguroglu Aysen Yarat Turay Yardimci Cihat Kucukhuseyin Levent Karaca Pakize Pasaoglu Emine Kokoglu Figen Aksoy Nejat Akar Luca Barella Hakan Berkkan Peter Butterworth Ayhan Dagdeviren David Dunger Tevfik Dorak Guido Frosina Müjdat Uysal Mustafa Kecer Nazmi Ozer Tevfik Akoglu Kubilay Karsidag Kilic Aydinli Aysel Aricioglu Nilgun Altan Mine Erdem Inal Alexander Levitzki Jose M. Ordovan Nesrin Kartal Özer Henrik Enghusen Poulsen Asuman Sunguroglu Barbara Tudek Turgut Ulutin Mark Wheatley Akin Yesilkaya Odysseas Zoras Ayse Ozer Emel Akoglu Canan Efendigil Karatay Nurten Turkozkan Serdar Ozturk Mustafa Keçer Filiz Aydin Ayça Vitrinel Aysun Pabuçcuoglu Meral Tolun Consultative Committee Bahattin Adam Turkey Abdülaziz A. Al-Khedhairy Riyadh, S. Arabia Mhamad Battikhi Zarga, Jordan George Birkmayer Vienna, Austria Fatima Cardoso Brussels, Belgium Özcan Erel Turkey Mehmet Gürtekin Turkey Hyung Hoan Lee Seoul, South Korea Ömer Küçük Detroit, MI, USA Werner Lichtenegge Berlin, Germany Joseph Molnar Szeged, Hungary Masato Nakamura Kanakawa, Japan Edith Olah Budapest, Hungary Duran Üstek Turkey Filiz Aydin Turkey Rolf F. Barth Columbus, OH, USA Asli Baykal Turkey Bela Bodey Reseda, CA, USA George Deliconstantinos Athens, Greece Ferit Gursu Turkey Ahmet Dirican Turkey Ferdane Kutlar Augusta, GA, USA Siriwat Klinbunga Bangkok, Thailand Yunus Luqmani Safat, Kuwait Kyriaki Mystakidou Athens, Greece Fatma Oguz Turkey Kia Rashidan Montreal, Canada ACKNOWLEDGMENTS ISTANBUL UNIVERSITY TUBITAK INTERNATIONAL UNION OF BIOCHEMISTRY AND MOLECULAR BIOLOGY (IUBMB) INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (I.I.A.R.) INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE (IFCC) Congress Secretariat TIJOEVENTS Emekli Subayevleri Tevfik Erdonmez Sk. 18. Blok D3 Esentepe-34394-Istanbul T. +90 212 275 46 63 PBX F. +90 212 275 46 68 info@tijoevents.com Department of molecular medicine, the institute of experimental medicine, university of istanbul Turgay Isbir Department of Molecular Medicine, Institue of Experimental Medical Research, Istanbul University, Istanbul, Turkey Turgay Isbir, PhD, Department of Molecular Medicine, The Institute of Experimental Medicine, Capa 34390, Istanbul, Turkey. Fax: +90 212 635 19 59. E-mail: tisbir@superonline.com Turgay Isbir is the Director of the Department of Molecular Medicine at the Institute For Experimental Medical Research at İstanbul University. He received his B.Sc. and Ph.D degrees from the Ankara University in the years of 1965 and 1969 respectively. Between the years of 1977–1978 he worked at the Department of Pharmacology in the Brain Research Council of Edinbrough University as a Research Fellow. He was nominated to Assoc. Prof. in Biochemistry in 1979 in the Medical Schoool of the Cukurova University in Adana. Between the years of 1985–1986 he worked as a Research Fellow at the Department of Heamatology of the Children's Hospital associated with the School Of Medicine of the University of Pennsylvenia. Dr. Isbir became Professor in Biochemistry in 1989 at Çukurova University in Adana. In 1997 he worked as a visiting Professor at the Department of Molecular Medicine in the Mayo Clinic located in Rochester. Currently his research interests are focused mainly on the relation between genetic polymorphisms and various types of cancer, lipid metabolism and genetic tendencies to cardiovascular diseases and diabetes in the Turkish population. He has authored over 100 articles and abstracts as well as one book chapter. Dr. Isbir is member to several International Scifientific Societies and is the Chairperson of the 'The Turkish Society of Molecular Medicine in Turkey. © 2009 IUBMB. Keywords: Molecular medicine; institution The Department of Molecular Medicine at the Istanbul University Institute of Experimental Medical Research is an interdiciplinary scientific branch that analyzes the molecular biology of cells and organisms, particularly from a medical point of view. Recent advances in molecular and cellular biology have required enormous amounts of research and practice. In all areas of medicine, molecular biology has played a key role and its importance to medical research is increasing every day. It is therefore impossible to disregard this fast-growing area. Biotechnology and molecular biology will certainly play major roles inclarifying the causes of some of the unsolved mysteries of modern medicine, such as heart disease, hypertension, major pyschiatric illness, rheumatic disease, and many others. Work in these fields may also help us to gain insight into broader aspects of human biology including development, aging, and evolution, adding to the importance and necessity of molecular medical research. Graduate students Masters and Ph.D. programs are offered in the Department of Molecular Medicine under the aegis of the Institute of Health Sciences. Graduate students at the department carry out thesis research under the supervision of staff members. Generally, these students have completed their major course work requirements for the M.S. and doctoral degrees and are engaged in full-time research. During the past few years, 13 students have worked here, supported by training grants to the University of Istanbul or by investigation research funds from the state. During the past 4 years, six students have completed their degrees in the Department of Molecular Medicine. The program allows young investigators to develop APOE, ACE, LPL, AGN, CETP, PON1, END1 and MTHFR skills in research methodology and interpretation. It is generally agreed that establishment of high technology in both medicine and biology will help Turkey in becoming a developed state. In other words, the status of a country that exports more than it imports isachieved only by maintaining enough technical knowledge of molecular biology, physiology, biophysics, biochemistry, genetics, and immunology, etc. (1–74). The University's Department of Molecular Medicine is involved in many aspects of metabolic diseases that affect several million people worldwide, including atherosclerosis, hypertension, diabetes, and Alzheimer's disease. Another branch of the department is dedicated to cancer research. In all of these areas, research on free oxygen radicals is being conducted, as well as molecular biological analyses of several substances such as apolipoprotein E, angiotensin, angiotensinogen, lipoprotein lipase, and cholesterol ester transfer protein poly-morphism. In the laboratory the application of molecular biological methods is used to assessthe prognosis and treatment of cancer. The main areas in our cancer research include myc protein, casein kinase, p53 protein, and glutation S-transferase polymorphism. REFERENCES 1 Unür M, Demirez E, Ağaçhan B, Görmüş U, Ergen A, Dalan B, Isbir T. (2008) The relationship of oral disturbances of diabetes mellitus patients with paraoxonase gene polymorphisms. Cell Biochem Funct. 11. [Epub ahead of print]. 2 Dalan AB, Ergen A, Yilmaz H, Karateke A, Isbir T. (2008) Manganese superoxide dismutase gene polymorphism, MnSOD plasma levels and risk ofepithelial ovarian cancer. J Obstet Gynaecol Res. 34, 878–884. 3 Tekeli A, Isbir S, Ergen A, Görmüş U, Bozkurt N, Timirci O, Arsan S, Isbir T. (2008) APE1 and XRCC3 polymorphisms and myocardial infarction. In Vivo. 22, 477–479. 4 Gözü A, Ergen A, Dayicioglu D, Yaylim I, Ozsoy Z, Isbir T. (2008) L-myc polymorphism in head and neck nonmelanoma skin and lower lip cancers. Arch Otolaryngol Head Neck Surg. 134, 725–728. 5 Yaylim-Eraltan I, Bozkurt N, Ergen A, Zeybek U, Ozturk O, Arikan S, Erbil Y, Uslu I, Camlica H, Isbir T. (2008) L-myc gene polymorphism and risk of thyroid cancer. Exp Oncol. 30, 117–120. 6 Ozger H, Kilicoglu O, Yilmaz H, Ergen HA, Yaylim I, Zeybek U, Isbir T. (2008) Methylenetetrahydrofolate reductase C677T gene polymorphism in osteosarcoma and chondrosarcoma patients. Folia Biol (Praha). 54, 53–57. 7 Ergen A, Isbir S, Tekeli A, Isbir T. (2008) Investigation of ABCA1 C69T and G-191C polymorphisms in coronary artery disease. In Vivo. 22, 187–190. 8 Gormus U, Ergen A, Yaylim-Eraltan I, Yilmaz H, Turna A, Bozkurt N, Isbir T. (2007) Fas-1377 A/G polymorphism in lung cancer. In Vivo. 21, 663–666. 9 Ergen HA, Narter F, Timirci O, Isbir T. (2007) Effects of manganase superoxide dismutase Ala-9Val polymorphism on prostate cancer: a case-control study. Anticancer Res. 27, 1227–1230. 10 Gormus U, Ergen A, Yilmaz H, Dalan B, Berkman S, Isbir T. (2007) Fas-1377A/G and FasL-844 T/C gene polymorphisms and epithelial ovarian cancer. Anticancer Res. 27, 991–994. 11 Isbir SC, Tekeli A, Ergen A, Yilmaz H, Ak K, Civelek A, Zeybek U, Arsan S. (2007) Genetic polymorphisms contribute to acute kidney injury after coronary artery bypass grafting. Heart Surg Forum. 10, E439–E444. 12 Ak K, Isbir S, Tekeli A, Ergen A, Atalan N, Dogan S, Civelek A, Arsan S. (2007) Presence of lipoprotein lipase S447X stop codon affects the magnitude of interleukin 8 release after cardiac surgery with cardiopulmonary bypass. J Thorac Cardiovasc Surg. 134, 477–483. 13 Aydin M, Ozkok E, Ozturk O, Agachan B, Yilmaz H, Yaylim I, Kebabcioglu S, Ispir T. (2007) Relationship between interleukin-8 and the oxidant-antioxidant system in end-stage renal failure patients. Exp Clin Transplant. 5, 610–613. 14 Yigit B, Bozkurt N, Narter F, Yilmaz H, Yucebas E, Isbir T. (2007) Effects of ACE I/D polymorphism on prostate cancer risk, tumor grade and metastatis. Anticancer Res. 27, 933–936. 15 Yaylim-Eraltan I, Arzu Ergen H, Arikan S, Okay E, Oztürk O, Bayrak S, Isbir T. (2007) Investigation of the VDR gene polymorphisms association with susceptibility to colorectal cancer. Cell Biochem Funct. 25, 731–737. 16 Zeybek U, Yaylim I, Yilmaz H, Ağaçhan B, Ergen A, Arikan S, Bayrak S, Isbir T. (2007) Methylenetetrahydrofolate reductase C677T polymorphism in patients with gastric and colorectal cancer. Cell Biochem Funct. 25, 419–422. 17 Kafadar AM, Yilmaz H, Kafadar D, Ergen A, Zeybek U, Bozkurt N, Kuday C, Isbir T. (2006) C677T gene polymorphism of methylenetetrahydrofolate reductase (MTHFR) in meningiomas and high-grade gliomas. Anticancer Res. 26, 2445–2449. 18 Zeybek U, Isbir T, Ergen HA, Yilmaz H, Hekim N, Akoglu E. (2006) Effects of cholesteryl ester transfer protein TAQ1B polymorphism in renal transplant patients. Transplant Proc. 38, 1382–1384. 19 Yigit B, Bozkurt N, Yaylim I, Titiz I, Isbir T. (2006) Analysis of L-myc gene polymorphism in patients with renal failure outcome to renal transplant. Transplant Proc. 38, 1267–1269. 20 Yigit B, Bozkurt N, Berber I, Titiz I, Isbir T. (2007) Analysis of CC chemokine receptor 5 and 2 polymorphisms and renal transplant survival. Cell Biochem Funct. 25, 423–426. 21 Bilge I, Sirin A, Agachan B, Emre S, Sadikoglu B, Yilmaz H, Sucu A, Isbir T. (2007) Is paraoxonase 192 gene polymorphism a risk factor for membranoproliferative glomerulonephritis in children? Cell Biochem Funct. 25, 159–165. 22 Kafadar AM, Ergen A, Zeybek U, Agachan B, Kuday C, Isbir T. (2006) Paraoxonase 192 gene polymorphism and serum paraoxonase activity in high grade gliomas and meningiomas. Cell Biochem Funct. 24, 455–460. 23 Hekim N, Ergen A, Yaylim I, Yilmaz H, Zeybek U, Oztürk O, Isbir T. (2007) No association between methylenetetrahydrofolate reductase C677T polymorphism and breast cancer. Cell Biochem Funct. 25, 115–117. 24 Okay E, Karadenizli A, Müezzinoglu B, Zeybek U, Arzu Ergen H, Isbir T. (2005) N-acetylcysteine attenuates bacterial translocation after partial hepatectomy in rats. J Surg Res. 127, 164–170. 25 Agachan B, Yilmaz H, Ergen HA, Karaali ZE, Isbir T. (2005) Paraoxonase (PON1) 55 and 192 polymorphism and its effects to oxidant-antioxidant system in turkish patients with type 2 diabetes mellitus. Physiol 54, 287–293. 26 Yilmaz H, Isbir S, Agachan B, Ergen A, Farsak B, Isbir T. (2006) C677T mutation methylenetetrahydrofolate reductase gene and serum homocysteine levels in Turkish patients with coronary artery disease. Cell Biochem Funct. 24, 87–90. 27 Biyikli NK, Alpay H, Yildiz N, Agachan B, Ergen A, Zeybek U, Bozkurt N, Ispir T. (2006) Paraoxonase 1 192 and 55 polymorphisms in nephrotic children. Pediatr Nephrol. 21, 649–654. 28 Karaali ZE, Agachan B, Yilmaz H, Isbir T. (2004) Angiotensin-converting enzyme I/D gene polymorphisms and effects of left ventricular hypertrophy in Turkish myocardial infarction patients. Acta Cardiol. 59, 493–497. 29 Yilmaz H, Agachan B, Ergen A, Karaalib ZE, Isbir T. (2004) Methylene tetrahydrofolate reductase C677T mutation and left ventricular hypertrophy in Turkish patients with type II diabetes mellitus. J Biochem Mol Biol. 37, 234–238. 30 Yilmaz H, Unlüçerçi Y, Gürdöl F, Isbilen E, Isbir T. (2004) Association of pre-eclampsia with hyperhomocysteinaemia and methylenetetrahydrofolate reductase gene C677T polymorphism in a Turkish population. Aust N Z J Obstet Gynaecol. 44, 423–427. 31 Yilmaz H, Isbir T, Agachan B, Karaali ZE. (2005) Effects of cholesterol ester transfer protein Taq1B gene polymorphism on serum lipoprotein levels in Turkish coronary artery disease patients. Cell Biochem Funct. 23, 23–28. 32 Arzu Ergen H, Hatemi H, Agachan B, Camlica H, Isbir T. (2004) Angiotensin-I converting enzyme gene polymorphism in Turkish type 2 diabetic patients. Exp Mol Med. 36, 345–350. 33 Agachan B, Yilmaz H, Isbir T, Akoglu E. (2004) Paraoxonase 192 polymorphism and its relationship to serum lipids in Turkish renal transplant recipients. Transplant Proc. 36, 1385–1386. 34 Oktem F, Sirin A, Bilge I, Emre S, Ağaçhan B, Ispir T. (2004) ACE I/D gene polymorphism in primary FSGS and steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 19, 384–389. 35 Yilmaz H, Agachan B, Karaali ZE, Isbir T. (2004) Taq1B polymorphism of CETP gene on lipid abnormalities in patients with type II diabetes mellitus. Int J Mol Med. 13, 889–893. 36 Agachan B, Yilmaz H, Karaali Z, Isbir T. (2004) Paraoxonase 55 and 192 polymorphism and its relationship to serum paraoxonase activity and serum lipids in Turkish patients with non-insulin dependent diabetes mellitus. Cell Biochem Funct. 22, 163–168. 37 Gürdöl F, Işbilen E, Yilmaz H, Isbir T, Dirican A. (2004) The association between preeclampsia and angiotensin-converting enzyme insertion/ deletion polymorphism. Clin Chim Acta. 341, 127–131. 38 Oztürk O, Isbir T, Yaylim I, Kocatürk CI, Gürses A. (2003) GST M1 and CYP1A1 gene polymorphism and daily fruit consumption in Turkish patients with non-small cell lung carcinomas. In Vivo. 17, 625–632. 39 Agachan B, Isbir T, Yilmaz H, Akoglu E. (2003) Angiotensin converting enzyme I/D, angiotensinogen T174M-M235T and angiotensin II type 1 receptor A1166C gene polymorphisms in Turkish hypertensive patients. Exp Mol Med. 35, 545–549. 40 Yaylim I, Bozkurt N, Yilmaz H, Isbir T, Isik N, Arikan S. (2003) The apolipoprotein E epsilon 4 allele is not a risk factor for Turkish breast cancer patients. Cancer Genet Cytogenet. 146, 86–87. 41 Isbir T, Yilmaz H, Agachan B, Karaali ZE. (2003) Cholesterol ester transfer protein, apolipoprotein E and lipoprotein lipase genotypes in patients with coronary artery disease in the Turkish population. Clin Genet. 64, 228–234. 42 Yilmaz H, Agachan B, Isbir T, Akoglu E. (2003) Is there additional effect of MTHFR C677T mutation on lipid abnormalities in renal allograft recipients? Transplant Proc. 35, 1390–1392. 43 Isbir T, Yaman A, Yaylim I, Yilmaz H, Oztürk O. (2003) Association between Apo B signal peptide gene polymorphism and NIDDM. Cell Biochem Funct. 21, 189–190. 44 Isbir T, Yaylim I, Arikan S, Kaytan E, Karşidağ T, Bayrak S, Camlica H. (2002) Close correlation between restriction fragment length polymorphism of L-myc gene and susceptibility to gastric cancer. Cancer Detect. 26, 454–457. 45 Isbir T, Yaylim I, Arîkan S, Küçücük S, Camlíca H. (2002) Increased frequency of the S-allele of the L-myc oncogene in breast cancer. Mol Med. 8, 521–524. 46 Yaylim I, Isbir T, Oztürk O, Turna A, Işitmangil T, Zonüzi F, Camlica H. (2002) Is there any correlation between restriction fragment length polymorphism of the L-MYC gene and metastasis of human nonsmall cell lung cancer? Cancer Genet Cytogenet. 134, 118–122. 47 Yaylim I, Isbir T. (2002) Enhanced casein kinase II (CK II) activity in human lung tumours. Anticancer Res. 22, 215–218. 48 Oztürk O, Yaylim I, Aydin M, Yilmaz H, Agaçhan B, Demiralp E, Isbir T. (2001) Increased plasma levels of interleukin-6 and interleukin-8 in beta-thalassaemia major. Haematologia. 31, 237–244. 49 Bozkurt N, Oztürk O, Isbir T. (2001) New MCAD gene mutation, not previously reported in other nations, found at A1161G in Turkish population. Am J Med Genet. 103, 255–256. 50 Isbir T, Agaçhan B, Yilmaz H, Aydin M, Kara I, Eker D, Eker E. (2001) Interaction between apolipoprotein-E and angiotensin-converting enzyme genotype in Alzheimer's disease. Am J Alzheimers Dis Other Demen. 16, 205–210. 51 Yilmaz H, Isbir T, Ağaçhan B, Aydin M. (2001) Is epsilon4 allele of apolipoprotein E associated with more severe end-organ damage in essential hypertension? Cell Biochem Funct. 19, 191–195. 52 Isbir T, Agaçhan B, Yilmaz H, Aydin M, Kara I, Eker E, Eker D. (2001) Apolipoprotein-E gene polymorphism and lipid profiles in Alzheimer's disease. Am J Alzheimers Dis Other Demen. 16, 77–81. 53 Ildan F, Göçer AI, Tuna M, Polat S, Kaya M, Isbir T, Cetinalp E. (2001) The effects of the pre-treatment of intravenous nimodipine on Na(+)-K+/Mg+2 ATPase, Ca+2/Mg+2 ATPase, lipid peroxidation and early ultrastructural findings following middle cerebral artery occlusion in the rat. Neurol Res. 23, 96–104. 54 Oztaş B, Kiliç S, Dural E, Ispir T. (2001) Influence of antioxidants on the blood-brain barrier permeability during epileptic seizures. J Neurosci Res. Nov 66, 674–678. 55 Oztaş B, Erkin E, Dural E, Isbir T. (2000) Influence of antioxidants on blood-brain barrier permeability during adrenaline-induced hypertension. Int J Neurosci. 105, 27–35. 56 Isbir T, Agaçhan B, Yilmaz H, Aydin M. (2000) Angiotensin converting enzyme gene polymorphism in Alzheimer's disease. Cell Biochem Funct. 18, 141–142. 57 Koç M, Ozener IC, Tezcan H, Bihorac A, Isbir T, Akoğlu E. (2000) Left ventricular hypertrophy and angiotensin-converting enzyme gene polymorphism in renal allograft recipients. Transplant Proc. 32, 542–544. 58 Isbir T, Yilmaz H, Ağaçhan B, Aydin M, Isbir CS. (1999) Association between angiotensin-converting enzyme gene polymorphism and coronary artery disease. IUBMB Life. 48, 205–207. 59 Isbir T, Yaylim I, Aydin M, Oztürk O, Koyuncu H, Zeybek U, Ağaçhan B, Yilmaz H. (2000) The effects of Brassica oleraceae var capitata on epidermal glutathione and lipid peroxides in DMBA-initiated-TPA-promoted mice. Anticancer Res. 20, 219–224. 60 Aydin M, Cengiz S, Agaçhan B, Yilmaz H, Isbir T. (2000) Age-related changes in GM1, GD1a, GT1b components of gangliosides in Wistar albino rats. Cell Biochem Funct. 18, 41–45. 61 Isbir T. (1999) The Department of Molecular Medicine at the University of Istanbul, Institute of Experimental Medical Research. Mol Med. 5, 69–70. 62 Isbir T, Yilmaz H, Bihorac A, Akoglu E. (1997) Mild-to-moderate hypertension and apolipoprotein E gene polymorphism. Am J Hypertens. 10, 827–828. 63 Koçak R, Başlamişli F, Güvenç B, Tamer L, Aikimbaev KS, Isbir T. (1996) Bencyclane as an anti-sickling agent. Br J Haematol. 92, 329–331. 64 Ildan F, Polat S, Göcer AI, Oner A, Isbir T, Mete UO, Kaya M, Karadayi A. (1996) The effects of the pretreatment of intravenous high dose methylprednisolone on Na(+)-K(+)/Mg(+2) ATPase and lipid peroxidation and early ultrastructural findings following middle cerebral artery occlusion in the rat. Acta Neurochir. 138, 338–345. 65 Ildan F, Polat S, Oner A, Isbir T, Cetinalp E, Kaya M, Karadayi A. (1995) The effect of the treatment of high-dose methylprednisolone on Na(+)-K(+)/Mg(+2) ATPase activity and lipid peroxidation and ultrastructural findings following cerebral contusion in rat. Surg Neurol. 44, 573–580. 66 Ildan F, Polat S, Oner A, Isbir T, Göçer AI, Tap O, Kaya M, Karadayi A. (1995) Effects of naloxone on sodium- and potassium-activated and magnesium-dependent adenosine-5'-triphosphatase activity and lipid peroxidation and early ultrastructural findings after experimental spinal cord injury. Neurosurgery. 36, 797–805. 67 Iteğin M, Günay I, Loğoğlu G, Isbir T. (1995) Effects of static magnetic field on specific adenosine-5'- triphosphatase activities and bioelectrical and biomechanical properties in the rat diaphragm muscle. Bioelectromagnetics. 16, 147–151. 68 Ildan F, Oner A, Polat S, Isbir T, Göcer AI, Kaya M, Karadayi A. (1995) Correlation of alterations on Na(+)-K+/Mg+2 ATPase activity, lipid peroxidation and ultrastructural findings following experimental spinal cord injury with and without intravenous methylprednisolone treatment. Neurosurg Rev. 18, 35–44. 69 Isbir T, Tamer L, Taylor A, Isbir M. (1994) Zinc, copper and magnesium status in insulin-dependent diabetes. Diabetes. 26, 41–45. 70 Yuregir GT, Donma O, Dikmen N, Isbir T, Cinar M. (1987) Population studies of hemoglobin S and other variants in Cukurova, the southern partof Turkey. Nippon Ketsueki Gakkai Zasshi. 50, 757–765. 71 Isbir T, Unal M, Yesilsoy C, Tukel S. (1987) Action of maprotiline on the erythrocyte membrane Na+-K+/Mg++ ATPase and Ca++/Mg++ ATPase in depressed patients. Int J. 34, 15–17. 72 Franklin SG, Wolf SI, Ozdemir Y, Yuregir GT, Isbir T, Blumberg BS. (1980) Albumin Naskapi variant in North American Indians and Eti Turks. Proc Natl Acad Sci U S A. 77, 5480–5482. 73 Reading HW, Isbir T. (1980) The role of cation-activated ATPases in transmitter release from the rat iris. Q J Exp Physiol Cogn Med Sci. 65, 105–116. 74 Reading HW, Isbir T. (1979) Action of lithium on ATPases in the rat iris and visual cortex. Biochem Pharmacol. 28, 3471–3474. Opening Lecture Kurt Wüthrich (Nobel Prize Winner)—Structural genomics-A new platform for drug discovery Kurt Wüthrich The Scripps Research Institute, La Jolla, CA, USA, and ETH Zurich, Zurich, Switzerland The determination of the human genome and the genomes of a large number of other species carries great promise with regard to improving the quality of life worldwide. New advances are expected in many different fields, including agriculture, nutrition and healthcare. Realization of these advances will have to be based on detailed knowledge of the proteome and other gene products, in addition to genomic DNA sequences. This lecture will reflect on strategic and practical aspects of this post-genomic research, with a special focus on establishing new platforms for drug discovery and drug design. PLENARY LECTURES Cell replacement therapy remains one of the most promising future approaches for treatment of Parkinson's disease (PD). Several sources have been evaluated for the generation of dopaminergic neurons. Currently, embryonic stem cells and possibly the recently induced pluripotent (iPS) cells represent an unlimited source for the derivation of all embryonic cell types. We have used mouse embryonic stem cell-derived dopaminergic neurons for transplantation into the 6-hydroxydopamine (6-OHDA)-rat model for Parkinson's disease. Our findings corroborate with results from other studies showing remarkable functional benefit in rat and primate model of Parkinson's disease. However, serious concerns are related to tumors due to the presence of few pluripotent cells. To eliminate such cells by specific labeling of DA neurons or their progenitors generally requires genetic manipulations. Therefore, one strategy to overcome these difficulties may consist in the derivation of neuronal precursor cells from embryonic stem cells, and to transplant these directly or after differentiation into DA neurons. We have isolated such cells from mouse and human embryonic stem cells. These neuronal stem cells (NSC) can be propagated in vitro and frozen for at least one year. They express the neural stem cell markers nestin, CD133 and musashi. Interestingly, the pluripotency marker Oct4 is not detected in these cells. Moreover, they have the potential to differentiate into dopaminergic neurons. Preliminary experiments indicate that mouse ES cell-derived neural stem cells do not form teratomas 3 months after injection into immunodeficient mice and rat. We are currently using mouse and human ES-cell derived neural stem cells for the transplantation into the 6-Hydroxydopmaine lesioned rat model for Parkinson's disease. Our studies will be presented. Acknowledgements: This project is supported by the Max-Planck society, the German Ministry of Research and Education (BMBF 01GN0510) and the Dr. Helmut Storz and Alte Leipziger Stiftung. The analysis of expressed proteins is an important developing area of research. Advances in technologies have led to a rapid increase in applications to a wide range of biological samples, such as plasma, urine, tissues, etc. The most widely used techniques for analysis of clinical samples are two-dimensional gel electrophoresis (2DE), to separate and visualize proteins, and mass spectrometry (MS) for protein identification. Furthermore, recently a complementary high-throughput proteomics platform, the Surface- Enhanced Laser Desorption Ionization (SELDI), has been developed. A primary aim of clinical proteomics is the identifications of biomarkers for early diagnosis, prognosis and therapeutic intervention of disease, by comparing the proteomic profiles of control and disease, and differing physiological states. Protein profiling is a promising tool for tumor characterization and the detection of biomarkers for prostate, bladder, lung, breast and ovarian cancer. For example, SELDI technique has been used to identify cancer-specific proteins in prostate cancer and to identify potential new markers in pancreatic adenocarcinoma, ovarian cancer and several potential urinary biomarkers in bladder cancer. The concept presented in these findings is that the diagnostic endpoint for cancer detection is not a single analyte, but a proteomic pattern that is composed of many individual proteins, each of which independently cannot differentiate diseased from healthy individuals. Moreover, proteomic analysis has been extensively applied to the discovery of potential diagnostic markers for other diseases, such as neurological disorders, Alzheimer's disease and profiling of urinary proteins to asses renal function. Several recent and ongoing studies have applied urinary proteomics to biomarker discovery for kidney diseases as well as other disorders that may have systemic alterations in metabolic and biochemical profiles that can affect urinary protein excretion. In diagnostic field, proteomic analysis could represent the right approach for discover and to identify early and predictive biomarkers of several and important diseases. Vitamin E is a typical antioxidant when studied in a test tube. However, like other antioxidants, in vivo this molecule has different properties, which are used to trigger cell information transfer and modulate gene transcription. We have shown that alpha-tocopherol (a-T) but not the very similar beta-tocopherol, is able to inhibit a master switch in cells, protein kinase C and consequently cell proliferation, inhibition of the NADPH oxidase assembly and inhibition of O2- production. Inhibition by a-T of the transcription of the gene coding for the scavenger receptor CD36 was the first observation, which was followed by a number of studies that have shown that several genes are regulated by vitamin E and none of them codes for antioxidant enzymes. Such an expression would be expected as a compensatory mechanism as a consequence of vitamin E diminution, in case that its action where that of an antioxidant. All the

Referência(s)
Altmetric
PlumX